Compare Extra Space Storage, Inc. (EXR) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Extra Space Storage, Inc. vs Incyte Corporation — how do they compare? Extra Space Storage, Inc. trades at $134.5 (market cap $28.12B), while Incyte Corporation trades at $112.77 (market cap $22.85B). The key difference: Extra Space Storage, Inc. is the larger of the two by market cap, and Extra Space Storage, Inc. pays a 4.87% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Extra Space Storage, Inc. for 109 Days and Incyte Corporation for 33 Days on average.
| EXR | INCY | |
|---|---|---|
Market Cap | $28.12B | $22.85B |
Volume | 2,595,579 | 1,927,029 |
Sector | Real Estate | Health |
52-Week High | $152.85 | $129.93 |
52-Week Low | $126.67 | $83.80 |
Typical Hold Time | 109 Days | 33 Days |
Enterprise Value | $41.84B | $18.35B |
Dividend Yield | 4.87% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Extra Space Storage (EXR) trades at $134.22, up 1.91% today, with a bearish technical signal but strong fundamentals including a 27.79% net income margin and consistent earnings beats. The company reported $3.38B in 2025 revenue, with a P/E of 29.39 and a consensus price target of $158.33. Recent news highlights executive leadership transition and a Q3 2026 earnings call scheduled for October 27, 2026.
Outlook is mixed: analyst consensus is evenly split between Buy and Hold, with upside potential from operational strength, but risks include high debt levels and bearish technical indicators. The stock offers a dividend yield supported by stable cash flows, though macroeconomic sensitivity and valuation premiums warrant caution.
Incyte (INCY) trades at $113.61, up 0.15% on the day, with a mixed technical signal leaning bearish. The company reported strong 2025 results with revenue of $5.14B and net income of $1.29B, and recent earnings beats in Q1 and Q2 2026. Key developments include FDA approval for Atebrioz and a strategic focus on post-JAKAFI growth targeting $4B in non-JAKAFI sales by 2029.
The outlook is cautiously optimistic, supported by robust profitability and pipeline progress, but tempered by near-term earnings pressure and technical weakness. Risks include JAKAFI's patent expiration after 2029 and competitive threats. Analysts maintain a Buy consensus with a $132.43 price target, implying significant upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Extra Space Storage, Inc.
Extra Space Storage is a fully integrated real estate investment trust that owns, operates, and manages almost 2,100 self-storage properties in 41 states, with over 160 million net rentable square feet of storage space. Of these properties, approximately one half is wholly owned, while some facilities are owned through joint ventures and others are owned by third parties and managed by Extra Space Storage in exchange for a management fee.
Read more on EXR →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
